MedTrace Logo

RGL-270 + ICI in Advanced NSCLC

NCT07652125 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-06-30

No results posted yet for this study

Summary

This is a single-center, open-label, investigator-initiated clinical trial. It aims to evaluate the safety and tolerability of RGL-270 in combination with a PD-1/PD-L1 inhibitor, to assess immunogenicity, preliminary efficacy, and exploratory biomarkers and to observe the safety and effectiveness of PD-1/PD-L1 inhibitor monotherapy in advanced NSCLC subjects through a real-world observational cohort.

Conditions

Interventions

BIOLOGICAL

RGL-270 in Combination with PD-1/PD-L1 Inhibitors

Personalized neoantigen mRNA vaccines

OTHER

Physician's Choice SOC

a real-world observational cohort as the parallel control

Sponsors & Collaborators

  • Shanghai Regenelead Theraples,Co,Ltd.

    collaborator UNKNOWN

  • Guangdong Association of Clinical Trials

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-25
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07652125 on ClinicalTrials.gov